Announcement by Chongqing Huasen Pharmaceutical Co., Ltd. Regarding the Death of an Independent Director of the Company

Log in to Sina Finance App and search for [Disclosure of Information] to see more evaluation levels

■

Chongqing Huasen Pharmaceutical Co., Ltd.

Announcement Regarding the Passing of Independent Director

Our company and all members of the board of directors guarantee that the information disclosed is true, accurate, and complete, with no false records, misleading statements, or major omissions.

Chongqing Huasen Pharmaceutical Co., Ltd. (hereinafter referred to as “the Company”) has learned that Mr. Li Jiaming, an independent director of the company, unfortunately passed away due to illness on March 19, 2026. The company and the board of directors express deep condolences and sincere sympathy to his family.

During his tenure as an independent director, chairman of the audit committee, and member of the compensation and assessment committee, Mr. Li Jiaming diligently fulfilled his duties with integrity and dedication, providing professional opinions and advice on relevant company decisions and actively safeguarding the interests of minority shareholders. The company and the board of directors sincerely thank Mr. Li Jiaming for his contributions during his term.

After Mr. Li Jiaming’s passing, the current number of board members has decreased from 9 to 8 (2 independent directors and 6 non-independent directors). This does not fall below the legal minimum, but it is below the number of directors and independent directors stipulated in the Articles of Incorporation. The number of independent directors is less than one-third of the board members, and the proportion of independent directors on the audit and compensation committees does not meet the majority requirement. Additionally, there is a lack of accounting professionals among the independent directors. The company will, in accordance with the Company Law, the Administrative Measures for Independent Directors of Listed Companies, the Articles of Incorporation, and other relevant regulations, promptly appoint new independent directors through proper procedures and fulfill disclosure obligations in a timely manner. The company’s production and operations will not be affected.

As of the date of this announcement, Mr. Li Jiaming did not hold any shares of the company.

This is hereby announced.

Chongqing Huasen Pharmaceutical Co., Ltd.

Board of Directors

March 19, 2026